Compare ENTA & PPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENTA | PPT |
|---|---|---|
| Founded | 1995 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 382.7M | 334.5M |
| IPO Year | 2012 | N/A |
| Metric | ENTA | PPT |
|---|---|---|
| Price | $12.66 | $3.44 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $20.40 | N/A |
| AVG Volume (30 Days) | ★ 172.5K | 104.7K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.84% |
| EPS Growth | ★ 29.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $102,814,000.00 | N/A |
| Revenue This Year | $7.76 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.48 | N/A |
| 52 Week Low | $6.44 | $3.41 |
| 52 Week High | $17.15 | $3.77 |
| Indicator | ENTA | PPT |
|---|---|---|
| Relative Strength Index (RSI) | 51.14 | 43.16 |
| Support Level | $11.92 | $3.42 |
| Resistance Level | $13.97 | $3.54 |
| Average True Range (ATR) | 0.79 | 0.02 |
| MACD | 0.13 | 0.00 |
| Stochastic Oscillator | 73.47 | 26.67 |
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Putnam Premier Income Trust is a closed-end fixed income fund that prominently invests in U.S. government, agency, high-yield, and international fixed income securities. The fund aims to provide high current income while preserving capital by diversifying across multiple bond markets beyond traditional benchmarks. Its portfolio includes various sectors such as investment-grade and high-yield corporate bonds, mortgage-backed securities, bank loans, and emerging market debt. Revenue for the trust is generated through interest income and capital gains from its investments in a fixed fund, which operates on the New York Stock Exchange and focuses on managing a diverse range of fixed-income assets across various countries.